3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
3
Sarcoma
2
Gastrointestinal
2
Breast
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
92
Nivolumab
57
Cyclophosphamide
22
Ipilimumab
17
atezolizumab
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
13
Radiosurgery
13
Paclitaxel
13
Interleukin-2
12
Docetaxel
12
fludarabine
11
Carboplatin
11
Pemetrexed
10
spartalizumab
9
Biopsy
9
durvalumab
8
Cisplatin
8
Radiotherapy
7
Immune Checkpoint Inhibitors
7
Blood Specimen Collection
7
cemiplimab
6
avelumab
6
aldesleukin
6
Taxes
6
Gemcitabine
6
Drug Therapy
6
Bevacizumab
6
trametinib
5
tislelizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
bempegaldesleukin
×
Thoracic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts